Phase 3 N=57 Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures
Blood Coagulation Disorders · Hemorrhage
Primary: Change in Hemoglobin Level — -0.6; -0.4 g/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=104 Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer
Rectal Cancer
Primary: 30-day Uncomplicated Perineal Wound Healing — 30; 33 Participants
Phase 3 N=162 Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
Chronic Severe Plaque-type Psoriasis
Primary: Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12 — 32; 31; 6; 26 Participants — p=<.0001
Phase 3 N=454 Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Primary: Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary Analysis — 198; 191 Participants — p=0.2874
Phase 3 N=114 Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment
Covid19
Primary: Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS. — 7; 7; 2; 2 days — p=0.05
Phase 3 N=485 A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine
Migraine
Primary: Time to Headache Pain Freedom — 4.0; 9.0 hours — p=0.0006
Phase 3 N=361 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: CR Rate — 42; 55; 134; 18 Participants
Phase 3 N=201 Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
Adenovirus Infection
Primary: Number of Participants With All-Cause Mortality — 9; 27; 8 Participants
Phase 3 N=93 Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Myasthenia Gravis, Generalized
Primary: Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test Results — 4.96; 3.86; 6.14…
Phase 3 N=8 Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
Schizophrenia
Primary: P50 Sensory Gating — 41.4; 80.2 percentage
Phase 3 N=397 A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
Ulcerative Colitis
Primary: Percentage of Participants With Both Clinical Response at Week 10 and Clinical Remission at Week 54, as Determined by the Mayo Clinic Score (MCS) — 18.6; 19.7 percentage…
Phase 3 N=154 Mepivacaine Versus Low-Dose Bupivacaine For Primary Total Hip and Knee Arthroplasty
Knee Osteoarthritis · Hip Osteoarthritis
Primary: Time to Return of Lower Extremity Motor Function — 210.3; 184.7 minutes
Phase 3 N=210 Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
Double-stranded DNA Virus
Primary: Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus — 15; 18; 39; 13 Participants
Phase 3 N=44 Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
Growth Hormone Deficiency
Primary: Annual Height Velocity (HV) After 12 Months — 9.78; 7.78 cm/year
Phase 3 N=1,961 STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Metabolism and Nutrition Disorder · Overweight or Obesity
Primary: Change in Body Weight (%) — -15.6; -2.8; -16.9; -3.1 Percentage point — p=<.0001